학술논문
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
Document Type
Article
Author
Source
In Gynecologic Oncology 1 May 2011 121(2):269-272
Subject
Language
ISSN
0090-8258